The STX1A (Syntaxin-1A) antibody is a tool used to detect Syntaxin-1A, a key protein involved in neurotransmitter release and synaptic vesicle fusion. Syntaxin-1A belongs to the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) family, which mediates membrane fusion events critical for intracellular transport and exocytosis. Primarily expressed in neuronal tissues, Syntaxin-1A localizes to presynaptic membranes, interacting with proteins like SNAP-25 and synaptobrevin to form the SNARE complex, enabling vesicle docking and calcium-triggered neurotransmitter release. Dysregulation of Syntaxin-1A is linked to neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and epilepsy, making it a focus of neurobiological research.
STX1A antibodies are widely employed in studies exploring synaptic function, protein interactions, and disease mechanisms. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, helping visualize expression levels, subcellular localization, and alterations in pathological conditions. Commercial STX1A antibodies are typically raised in rabbits or mice, targeting specific epitopes within the protein’s N-terminal or C-terminal domains. Validation steps, such as knockout controls, ensure specificity. Beyond research, STX1A antibodies hold potential in diagnostic applications, aiding biomarker identification for neurodegenerative diseases, and in drug development targeting synaptic transmission pathways.